Who we are
BBS’s competence is in R&D and manufacturing the implants. The production facility, located in Reisjärvi received authorization for commercial production 2015. The clinical trial is in follow-up phase, all the patients have been operated. BBS will initially enter foot and ankle area and at a later stage expand to other indications such as spinal fusions. It is expected to get CE-mark in 2017. FDA approval is in process.
Our fisrt product, ARTEBONE, is paste in a ready to use syringe. Coated granules and blocks are under development. The implant is based on reindeer bone protein extract containing the whole spectrum of natural bone growth factors and proteins. ARTEBONE is aimed for orthopaedic and trauma surgery. Approvals for dental, maxillofacial and veterinary indications are in scope.
• Outstanding performance at a moderate price
• Extremely safe, no human disease transmission
• Easy and ready to use in a syringe
• Reduces operating time and costs
• Excellent batch-to-batch consistency
• A natural product from renewable raw material
What we are looking for
We are looking for partners and investors.
Pekka Jalovaara, MD, PhD, Professor of Orthopaedic Surgery, CEO
Mikko Viitanen, M.Sc. (Biochem., Eng.) Director, Research Operations&Analytics
Hanna Tölli, M.Sc (Medical Eng.)PhD, Chief of Product and Process Development
Merja Haikola, MSc, Chem., Quality Assurance/Quality Control
Anja Taube-Siikavirta, M. Sc. (Pharm.)
Matti Viluksela, PhD , Professor of Toxicology, Preclinical & Clinical Development
Kenneth Sandstöm, M.Sc. Chem., Project Manager, Product Development
Elli Birr, M.Sc. (Biol.), PhD Assistant, Quality Assurance